Consulting Services

August 2023 Question of the Month

What steps do you take when learning about an electronic prescribing challenge?

Root cause analysis: 0%

Compendia review: 0%

Engage a partner: 0%

All of the above: 50%

None of the above: 50%

Does your organization have a strategy for Humira biosimilar launches?

Yes, well defined: 0%

We have a framework: 50%

Waiting for clarity: 0%

No: 0%

Unaware of need: 50%

How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?

During Phase II Trials: 0%

Initiation of Phase III Trials: 66%

6 months prior to approval: 33%

3 months prior to approval: 0%

At time of approval: 0%

After approval: 0%

No strategy: 0%